/
References within this Annual Report to Tandem, we, our, us, management, or the Company refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries. Overview Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management.
$20.36
$0.32 (-1.55%)
Price from 40 days ago
The business is unprofitable at the operating level (-18.45% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.9%, steady but not accelerating. Margins contracted 7.9pp, which offsets some of the top-line progress.
Free cash flow declined 694% versus the prior year, cash generation momentum has weakened. ROIC dropped from -10.68% to -22.14%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.03B
▲ +7.9% YoY
Net Income (TTM)
-$95M
▼ -113.2% YoY
Op. Margin
-8.16%
▼ -7.9pp YoY
ROIC
-10.07%
▼ -11.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▼ -694.1% YoY
Op. Cash Flow (TTM)
$20M
▼ -140.1% YoY
Net Debt
$164M
Cash & Equiv.
$570M
5Y CAGR: +15.3%
Continue Research